Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Key Documents

View All Documentation

Z-005

Supelco

Zonisamide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór empiryczny (zapis Hilla):
C8H8N2O3S
Numer CAS:
68291-97-4
Masa cząsteczkowa:
212.23
Numer WE:
200-659-6
Numer MDL:
MFCD00865316
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
329831593
NACRES:
NA.24

klasa czystości

certified reference material

Postać

liquid

Właściwości

Snap-N-Spike®/Snap-N-Shoot®

opakowanie

ampule of 1 mL

producent / nazwa handlowa

Cerilliant®

stężenie

1.0 mg/mL in methanol

metody

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Zastosowanie

clinical testing

format

single component solution

temp. przechowywania

−20°C

ciąg SMILES

NS(CC1=NOC2=C1C=CC=C2)(=O)=O

InChI

1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)

Klucz InChI

UBQNRHZMVUUOMG-UHFFFAOYSA-N

informacje o genach

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Powiązane kategorie

Opis ogólny

Zonisamide is a second-generation anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures, infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, and generalized tonic-clonic seizure. Zonisamide is marketed in the US under the trade name Zonegran®.

Zastosowanie


  • Analysis of environmental samples: Instrument Response Standard for X-Ray Powder Diffraction was utilized for the dispersive magnetic micro solid phase extraction of pollutants in water samples and creams. This technique is vital for scientists engaged in environmental monitoring and contamination studies (Jalilian et al., 2019).

  • Food safety testing: The standard supported efficient extraction and determination methods for Rhodamine B in food samples, underscoring its importance in food safety and quality control labs focused on consumer health protection (Hu et al., 2019).

  • Advanced material characterization: A core-shell indium (III) sulfide@metal-organic framework nanocomposite used for the extraction of nitro-polycyclic aromatic hydrocarbons employs Instrument Response Standards to ensure accurate characterization of nanocomposite properties, critical for researchers developing new materials (Jia et al., 2018).


Informacje prawne

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zonegran is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd.
This page may contain text that has been machine translated.

produkt powiązany

Numer produktu
Opis
Cennik

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

H225,H301 + H311 + H331,H370

Klasyfikacja zagrożeń

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organy docelowe

Eyes

Kod klasy składowania

3 - Flammable liquids

Klasa zagrożenia wodnego (WGK)

WGK 2

Temperatura zapłonu (°F)

49.5 °F - closed cup

Temperatura zapłonu (°C)

9.7 °C - closed cup

Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

M E Choudhury et al.
European journal of pharmacology, 689(1-3), 72-80 (2012-06-05)
Zonisamide has been proven as an effective drug for the recovery of degenerating dopaminergic neurons in the animal models of Parkinson's disease. However, several lines of evidence have questioned the neuroprotective capacity of zonisamide in animal models of Parkinson's disease.
Yuto Ueda et al.
Biochemical and biophysical research communications, 428(3), 401-404 (2012-10-30)
The anti-epileptic drug zonisamide is reported to exert beneficial effects in patients with Parkinson's disease. To elucidate the pathophysiological mechanisms underlying the anti-parkinsonism effects of zonisamide, we examined the effect of zonisamide co-administered with levodopa in the striata of rats
Combination therapy of zonisamide with aripiprazole on ECT- and benzodiazepine-resistant periodic catatonia.
Masanori Nakagawa et al.
The Journal of neuropsychiatry and clinical neurosciences, 24(3), E9-E9 (2012-10-06)
M J Brodie et al.
Acta neurologica Scandinavica. Supplementum, (194)(194), 19-28 (2012-11-01)
Zonisamide is a benzisoxazole derivative, chemically unrelated to other antiepileptic drugs, that appears to have multiple mechanisms of action, including inhibition of Na(+) channels and reduction of T-type Ca(2+) currents. It is currently licensed in Europe and the USA for
Michel Baulac et al.
The Lancet. Neurology, 11(7), 579-588 (2012-06-12)
Additional options are needed for monotherapy treatment of adults newly diagnosed with partial epilepsy. This trial compares the efficacy and tolerability of once-daily zonisamide with twice-daily controlled-release carbamazepine monotherapy for such patients. In this phase 3, randomised, double-blind, parallel-group, non-inferiority
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej